glofitamab
roche
['glofitamab', 'lymphoma', 'lymsm']
congress #eha2023 | describes a phase ii trial of glofitamab in pts with r/r lbcl. n=154. after a median fu =18.3 months, 39/59 pts who achieved cr were ongoing. median duration of cr =24.1 months. 18-month os rate =80% #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm